Thierry Gorlia

Research interests

Publications

• Transcriptome analysis reveals tumor microenvironment changes in glioblastoma

  Cancer Cell · 2023 · 10.1016/j.ccell.2023.02.019

• Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study

  The Lancet Oncology · 2021 · https://doi.org/10.1016/s1470-2045(21)00090-5

• Automated quantitative tumour response assessment of MRI in neuro-oncology with artificial neural networks: a multicentre, retrospective study

  The Lancet Oncology · 2019 · https://doi.org/10.1016/s1470-2045(19)30098-1

• Novel, improved grading system(s) for IDH-mutant astrocytic gliomas

  Acta Neuropathologica · 2018 · https://doi.org/10.1007/s00401-018-1849-4

• Lomustine and Bevacizumab in Progressive Glioblastoma

  New England Journal of Medicine · 2017 · https://doi.org/10.1056/nejmoa1707358

• Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study

  The Lancet · 2017 · https://doi.org/10.1016/s0140-6736(17)31442-3

• Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(16)30313-8

• Corticosteroids compromise survival in glioblastoma

  Brain · 2016 · https://doi.org/10.1093/brain/aww046

• Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

  The Lancet Oncology · 2014 · https://doi.org/10.1016/s1470-2045(14)70379-1

• Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951

  Journal of Clinical Oncology · 2012 · https://doi.org/10.1200/jco.2012.43.2229

• Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas

  The Lancet Oncology · 2011 · https://doi.org/10.1016/s1470-2045(11)70057-2

• Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma

  Neurology · 2011 · 10.1212/wnl.0b013e31822f02e1

• IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group

  Clinical Cancer Research · 2010 · https://doi.org/10.1158/1078-0432.ccr-09-2902

• MGMT Promoter Methylation Is Prognostic but Not Predictive for Outcome to Adjuvant PCV Chemotherapy in Anaplastic Oligodendroglial Tumors: A Report From EORTC Brain Tumor Group Study 26951

  Journal of Clinical Oncology · 2009 · 10.1200/jco.2009.24.1034

• Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

  The Lancet Oncology · 2009 · https://doi.org/10.1016/s1470-2045(09)70025-7

• Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034

  Journal of Clinical Oncology · 2009 · https://doi.org/10.1200/jco.2008.17.5984

• Long-Term Efficacy Results of EORTC Genito-Urinary Group Randomized Phase 3 Study 30911 Comparing Intravesical Instillations of Epirubicin, Bacillus Calmette-Guérin, and Bacillus Calmette-Guérin plus Isoniazid in Patients with Intermediate- and High-Risk Stage Ta T1 Urothelial Carcinoma of the Bladder

  European Urology · 2009 · https://doi.org/10.1016/j.eururo.2009.12.024

• Stem Cell–Related “Self-Renewal” Signature and High Epidermal Growth Factor Receptor Expression Associated With Resistance to Concomitant Chemoradiotherapy in Glioblastoma

  Journal of Clinical Oncology · 2008 · 10.1200/jco.2007.15.7164

• Anti‐O6‐Methylguanine‐Methyltransferase (MGMT) Immunohistochemistry in Glioblastoma Multiforme: Observer Variability and Lack of Association with Patient Survival Impede Its Use as Clinical Biomarker*

  Brain Pathology · 2008 · https://doi.org/10.1111/j.1750-3639.2008.00153.x

• Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3

  The Lancet Oncology · 2007 · https://doi.org/10.1016/s1470-2045(07)70384-4

• Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer

  New England Journal of Medicine · 2007 · https://doi.org/10.1056/nejmoa071028

• Adjuvant Procarbazine, Lomustine, and Vincristine Improves Progression-Free Survival but Not Overall Survival in Newly Diagnosed Anaplastic Oligodendrogliomas and Oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III Trial

  Journal of Clinical Oncology · 2006 · https://doi.org/10.1200/jco.2005.04.6078

• Radiotherapy and Temozolomide for Newly Diagnosed Glioblastoma: Recursive Partitioning Analysis of the EORTC 26981/22981-NCIC CE3 Phase III Randomized Trial

  Journal of Clinical Oncology · 2006 · https://doi.org/10.1200/jco.2005.04.5963

• Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma

  New England Journal of Medicine · 2005 · https://doi.org/10.1056/nejmoa043330

• MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma

  New England Journal of Medicine · 2005 · https://doi.org/10.1056/nejmoa043331

• Phase II Study of First-Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors: The European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971

  Journal of Clinical Oncology · 2003 · 10.1200/jco.2003.12.015

Current projects

No projects listed.